Simeon George
Chief Executive Officer @ SR One
San Francisco, United States
Simeon George is a Series B investor at SR One in San Francisco focused on Biotechnology and Medical. Simeon joined SR One in 2007 and leads SR Ones investment activities on the West Coast. Prior to joining SR One, Simeon was a consultant at Bain & Company and an investment banker at Goldman Sachs and Merrill Lynch.Simeon received his BA in Neuroscience from the Johns Hopkins University, where he graduated Phi Betta Kappa. Simeon receivedhis MD from the University of Pennsylvania School of Medicine and his MBA (Mayer Scholar) from the Wharton School of the University of Pennsylvania.
- Total investments:
- 24
- Last investment:
- Lead investor:
- 46%
Last updated:
For AI agents: llms.txt
Industries Simeon George invests in
Stages Simeon George invests in
Countries Simeon George invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 13 (54%)
- Medical 7 (29%)
- Health Care 6 (25%)
- Life Science 6 (25%)
- Therapeutics 4 (17%)
Stage
- Series B 9 (38%)
- Series A 6 (25%)
- Series C 2 (8%)
- Series D 2 (8%)
- Private Equity 1 (4%)
Country
- United States 13 (54%)
- Israel 1 (4%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| We are a precision oncology company pioneering the development of cancer therapies guided by our proprietary functional genomics. | $67.4M / Series D / Jul 07, 2026 | ||
| We are a precision oncology company pioneering the development of cancer therapies guided by our proprietary functional genomics. | $40.2M / Series D / May 06, 2025 | ||
| ADARx Pharmaceuticals is a genetic medicine company focusing on the base editing of mRNA transcripts. It discovers and develops innovative therapeutics that can utilize a family of endogenous enzymes called adenosine deaminase acting on RNA (ADAR) to precise target and correct single point mutations on an mRNA, thus the production of desired andfunctional protein is restored. It was founded in 2019 and is headquartered in San Diego, California. | $200M / Series C / Aug 09, 2023 | ||
| ADARx Pharmaceuticals is a genetic medicine company focusing on the base editing of mRNA transcripts. It discovers and develops innovative therapeutics that can utilize a family of endogenous enzymes called adenosine deaminase acting on RNA (ADAR) to precise target and correct single point mutations on an mRNA, thus the production of desired andfunctional protein is restored. It was founded in 2019 and is headquartered in San Diego, California. | $46M / Series B / Jan 20, 2023 | ||
| Rezo Therapeutics identifies targets and therapies by combining distinct, unbiased technologies with artificial intelligence. Rezo's proprietary platform can be used to treat a wide range of diseases. Rezo's initial focus is oncology, with plans to expand into other therapeutic areas through collaborations and partnerships. | $78M / Series A / Nov 17, 2022 | ||
| Simcha Therapeutics is a biopharmaceutical company developing engineered cytokine immunotherapy for cancer. The company uses directed evolution to engineer novel cytokines designed to unlock the precision and power of the immune system. Simcha’s lead program, ST-067, is a designer IL-18 cytokine that has shown potent antitumor effects in animalmodels, both as a monotherapy and when combined with anti-PD-1 checkpoint inhibitors, as described in Nature in June 2020.It was founded in 2018 and is headquartered in New Haven, Connecticut, USA. | $40M / Series B / Jan 27, 2022 | ||
| ADARx Pharmaceuticals is a genetic medicine company focusing on the base editing of mRNA transcripts. It discovers and develops innovative therapeutics that can utilize a family of endogenous enzymes called adenosine deaminase acting on RNA (ADAR) to precise target and correct single point mutations on an mRNA, thus the production of desired andfunctional protein is restored. It was founded in 2019 and is headquartered in San Diego, California. | $75M / Series B / Sep 08, 2021 | ||
| Design Therapeutics is a biotechnology company developing a new class of therapies for serious degenerative disorders caused by nucleotide repeat expansions. The company’s lead program is focused on the treatment of Friedreich’s ataxia and discovery efforts are ongoing in other degenerative diseases. | $125M / Series B / Jan 27, 2021 | ||
| Design Therapeutics is a biotechnology company developing a new class of therapies for serious degenerative disorders caused by nucleotide repeat expansions. The company’s lead program is focused on the treatment of Friedreich’s ataxia and discovery efforts are ongoing in other degenerative diseases. | $45.5M / Series A / Mar 20, 2020 | ||
| Turning Point Therapeutics is a clinical-stage structure-based drug design company for the discovery and development of precision medicines for cancer and other diseases. They focus on the design of novel chemical identities for established oncogene drivers with secondary resistant mutations, newly identified disease-driven targets, and potentialtargets regulating the tumor microenvironment and tumor immunity. | $80M / Private Equity / Oct 19, 2018 | ||
| See all 24 investments → | |||
Co-Investors
About SR One
SR One is the corporate venture capital arm of GlaxoSmithKline. The firm invests globally in emerging life science companies that are pursuing innovative science which will significantly impact medical care. Since 1985, SR One has invested approximately 800 million in more than 180 companies.
SR One Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Jill Carroll
Partner
|
|||
|
Simeon George
Chief Executive Officer
|
|||
Christopher Y. Chai
Venture Partner
|
|||
Iqbal Mufti
Partner
|
|||
Jens Eckstein
President
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Simeon George invest in?
Simeon George invests primarily in Biotechnology, Medical and Health Care startups, most often at Series B and Series A stage. Most of the 24 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Simeon George?
Public channels for Simeon George include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Simeon George last invest?
The most recent investment recorded for Simeon George closed in Jul 2026. Shizune tracks 24 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
